Deferoxamine
- Generic Name
- Deferoxamine
- Brand Names
- Desferal
- Drug Type
- Small Molecule
- Chemical Formula
- C25H48N6O8
- CAS Number
- 70-51-9
- Unique Ingredient Identifier
- J06Y7MXW4D
Overview
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Background
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Indication
Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
Associated Conditions
- Aluminum overload
- Chronic Iron Overload
- Chronic aluminum overload
- Iron Overload
Clinical Trials
FDA Approved Products
Deferoxamine Mesylate
Manufacturer:Hospira, Inc.
Route:INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Strength:2 g in 1 1
Approved: 2023/03/01
NDC:0409-2337
Deferoxamine mesylate
Manufacturer:Apotex Corp.
Route:INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Strength:500 mg in 1 1
Approved: 2023/12/01
NDC:60505-6238
Deferoxamine mesylate
Manufacturer:Alvogen Inc.
Route:INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Strength:500 mg in 1 1
Approved: 2017/10/07
NDC:47781-623
Deferoxamine mesylate
Manufacturer:Gland Pharma Limited
Route:INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Strength:500 mg in 1 1
Approved: 2023/07/28
NDC:68083-172
Deferoxamine mesylate
Manufacturer:Gland Pharma Limited
Route:INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Strength:2 g in 1 1
Approved: 2023/07/28
NDC:68083-173
Singapore Approved Products
DBL DESFERRIOXAMINE MESYLATE FOR INJECTION BP 500 mg/vial
Manufacturer:Hospira Australia Pty Ltd
Form:INJECTION, POWDER, FOR SOLUTION
Strength:500 mg/vial
Online:Yes
Approved: 1998/06/04
Approval:SIN09794P
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath